Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia

Pediatric Blood and Cancer

Volumn 44, Issue 1, 2005, Pages 63-69

  Hijiya, Nobuko ^a,b   Metzger, Monika L ^a   Pounds, Stan ^a,b   Schmidt, Jeffrey E ^a,b   Razzouk, Bassem I ^a,b   Rubnitz, Jeffrey E ^a,b   Howard, Scott C ^a,b   Nunez, Cesar A ^a,b   Pui, Ching Hon ^a,b   Ribeiro, Raul C ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

AML; Cytokines; Early complications; Monocytic leukemia; Myelomonocytic leukemia; SIRS; Tumor lysis

Indexed keywords

ADRENALIN; CLADRIBINE; CYTARABINE; DAUNORUBICIN; DOPAMINE; NORADRENALIN;

ACUTE MYELOMONOCYTIC LEUKEMIA; BRONCHOSPASM; CANCER CHEMOTHERAPY; CARDIOPULMONARY INSUFFICIENCY; CHILD; CLINICAL ARTICLE; CYTOLYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN SYNDROME; EXPERIENCE; FEMALE; FEVER; HUMAN; HYPERTHERMIA; HYPOTENSION; INFORMATION; LEUKEMIA CELL; MALE; MEDICAL RECORD; MYELOMONOCYTIC LEUKEMIA; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TACHYCARDIA; TREATMENT OUTCOME; TUMOR CELL DESTRUCTION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 10044273251     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20192     Document Type: Review

References (32)

1. Gatta G, Capocaccia R, Coleman MP, et al. Childhood cancer survival in Europe and the United States. Cancer 2002;95:1767-1772.
2. Gatta G, Luksch R, Coleman MP, et al. Survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) in European children since 1978: A population- based study. Eur J Cancer 2001;37:695-702.
3. Burnett AK. Treatment of acute myeloid leukaemia in younger patients. Best Pract Res Clin Haematol 2001;14:95-118.
4. Tryka AF, Godleski JJ, Fanta CH. Leukemic cell lysis pneumonopathy. A complication of treated myeloblastic leukemia. Cancer 1982;50:2763-2770.
5. Dombret H, Hunault M, Faucher C. et al. Acute lysis pneumopathy after chemotherapy for acute myelomonocytic leukemia with abnormal marrow eosinophils. Cancer 1992;69:1356-1361.
6. Lester WA, Hull DR, Fegan CD, et al. Respiratory failure during induction chemotherapy for acute myelomonocytic leukaemia (FAB M4Eo) with ara-C and all-trans retinoic acid. Br J Haematol 2000;109:847-850.
7. Perez-Zincer F, Juturi JV, Hsi ED, et al. A pulmonary syndrome in patients with acute myelomonocytic leukemia and inversion of chromosome 16. Leuk Lymphoma, 2003;44:103-109.
8. Myers TJ, Cole SR, Klatsky AU, et al. Respiratory failure due to pulmonary leukostasis following chemotherapy of acute nonlymphocytic leukemia. Cancer 1983;51:1808-1813.
9. Wan TS, Yip SF, Yeung YM, et al. Fatal diffuse alveolar damage complicating acute myeloid leukemia with abnormal eosinophils and trisomy X. Ann Hematol 2002;81:167-169.
10. Botwinski CA. Systemic inflammatory response syndrome. Neonatal Netw 2001;20:21-28.
11. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
12. Razzouk BI, Raimondi SC, Srivastava DK, et al. Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: A single institution's experience. Leukemia 2001;15:1326-1330.
13. Crews KR, Gandhi V, Srivastava DK, et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol 2002;20:4217-4224.
14. Chiang LK, Dunn AE. Cardiology. In: Siberry GK, lannone R, editors. The Harriet Lane handbook. 15th edition. St. Louis, MO: Mosby; 2000. pp 131-180.
15. Pagano M, Gaurrean K. Principles of biostatistics. 2nd edition. Pacific Grove, CA: Duxbury Press; 2000.
16. Graybill FA. Theory and application of the linear model. Pacific Grove: Wadsworth & Brooks/Cole; 1976.
17. Hocking RR. Methods and applications of linear models. New York: John Wiley & Sons; 1996.
18. Kuehl R. Statistical principles of research design and analysis. Belmont, California: Duxbury Press; 1994. pp 168-175.
19. Crews KR, Wimmer PS, Hudson JQ, et al. Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. J Pediatr Hematol Oncol 2002;24:677-680.
20. Schmidt JE, Tamburro RF, Sillos EM, et al. Pathophysiology-directed therapy for acute hypoxemic respiratory failure in acute myeloid leukemia with hyperleukocytosis. J Pediatr Hematol Oncol 2003;25:569-571.
21. Stapleton FB, Strother DR, Roy S III, et al. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics 1988;82:863-869.
22. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-214.
23. Griffin JD, Rambaldi A, Vellenga E, et al. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood 1987;70:1218-1221.
24. Rodriguez-Cimadevilla JC, Beauchemin V, Villeneuve L, et al. Coordinate secretion of interleukin-1 beta and granulocyte-macrophage colony-stimulating factor by the blast cells of acute myeloblastic leukemia: Role of interleukin-1 as an endogenous inducer. Blood 1990;76:1481-1489.
25. Stucki A, Rivier AS, Gikic M, et al. Endothelial cell activation by myeloblasts: Molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001;97:2121-2129.
26. Kurzrock R, Kantarjian H, Wetzler M, et al. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp Hematol 1993;21:80-85.
27. Seftel MD, Bruyere H, Copland M, et al. Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22). Eur J Haematol 2002;69:193-199.
28. Wardlaw AJ, Kay BA. Eosinophils and their disorders. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, editors. Williams hematology, 6th edition. New York: McGraw-Hill; 2003. pp 785-799.
29. Markman M, Howell SB, King M, et al. Anaphylactic reaction to cytarabine: In vitro evidence that the response is immunoglobulin E mediated. Med Pediatr Oncol 1984;12:201-203.
30. Ek T, Jarfelt M, Mellander L, et al. Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children. Med Pediatr Oncol 2001;37:459-464.
31. Lichtman MA, Rowe JM. Hyperleukocytic leukemias: Rheological, clinical, and therapeutic considerations. Blood 1982;60:279-283.
32. Farley-Hills E, Byrne AJ, Brennan L, et al. Tumour lysis syndrome during anaesthesia. Paediatr Anaesth 2001;11:233-236.